New York State Teachers Retirement System Purchases Shares of 42,927 TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Teachers Retirement System acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 42,927 shares of the biopharmaceutical company’s stock, valued at approximately $1,004,000.

Other institutional investors have also recently made changes to their positions in the company. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the period. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics during the 2nd quarter valued at about $35,000. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at about $53,000. Finally, Values First Advisors Inc. acquired a new position in TG Therapeutics in the 3rd quarter worth about $58,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on TGTX. HC Wainwright boosted their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. B. Riley boosted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

TG Therapeutics Stock Up 3.3 %

Shares of NASDAQ:TGTX opened at $28.81 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $9.81 and a fifty-two week high of $28.92. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The firm’s 50-day simple moving average is $23.84 and its 200-day simple moving average is $20.50. The company has a market cap of $4.46 billion, a price-to-earnings ratio of -288.07 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.65% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The company’s quarterly revenue was down 49.4% compared to the same quarter last year. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.15 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.